OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial

Philip J. Mease, H. Kellner, Akimichi Morita, A. Kivitz, Kim Papp, Stella Aslanyan, Bret Berner, S. Chen, Ann Eldred, Frank Behrens

Annals of the Rheumatic Diseases · 2018 · 53 citations · 1 references

DOIFull text

Open access

Concepts

References

1